{
  "version": "base-2024-04-04",
  "scanId": "6db62c55-49a0-41d0-b1c4-c2a6c006bd4f",
  "documents": [
    {
      "average_generated_prob": 0,
      "class_probabilities": {
        "ai": 0.009092464091054084,
        "human": 0.990907535908946,
        "mixed": 0
      },
      "completely_generated_prob": 0.009092464091054084,
      "confidence_category": "high",
      "confidence_score": 0.990907535908946,
      "confidence_scores_raw": {
        "identity": {
          "ai": 0.009092464091054084,
          "human": 0.990907535908946,
          "mixed": 0
        }
      },
      "confidence_thresholds_raw": {
        "identity": {
          "ai": {
            "low": 0.82,
            "medium": 0.92,
            "reject": 0.8
          },
          "human": {
            "low": 0.85,
            "medium": 0.95,
            "reject": 0.75
          },
          "mixed": {
            "low": 0.85,
            "medium": 0.92,
            "reject": 0.8
          }
        }
      },
      "overall_burstiness": 27.432239532470703,
      "paragraphs": [
        {
          "completely_generated_prob": 4.188724873543098e-08,
          "num_sentences": 9,
          "start_sentence_index": 0
        }
      ],
      "predicted_class": "human",
      "sentences": [
        {
          "generated_prob": 0.00021788735466543585,
          "perplexity": 91,
          "sentence": "Geneva/Oslo 22 January 2021 - COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income level, today announced the signing of an advance purchase agreement with Pfizer for up to 40 million doses of the Pfizer-BioNTech vaccine candidate, which has already received WHO Emergency Use Listing.",
          "highlight_sentence_for_ai": false
        },
        {
          "generated_prob": 0.0002599605650175363,
          "perplexity": 104,
          "sentence": "Rollout will commence with the successful negotiation and execution of supply agreements.",
          "highlight_sentence_for_ai": false
        },
        {
          "generated_prob": 0.00021484818716999143,
          "perplexity": 52,
          "sentence": "In further support of its mission to expedite early availability of vaccines to lower-income countries and help bring a rapid end to the acute stage of the COVID-19 pandemic, COVAX also confirmed today that it will exercise an option - via an existing agreement with Serum Institute of India (SII) - to receive its first 100 million doses of the AstraZeneca/Oxford University-developed vaccine manufactured by SII.",
          "highlight_sentence_for_ai": false
        },
        {
          "generated_prob": 0.0002190751547459513,
          "perplexity": 80,
          "sentence": "Of these first 100 million doses, the majority are earmarked for delivery in the first quarter of the year, pending WHO Emergency Use Listing.",
          "highlight_sentence_for_ai": false
        },
        {
          "generated_prob": 0.0002257094602100551,
          "perplexity": 77,
          "sentence": "The WHO review process, which is currently underway, follows approval for restricted use in emergency situations by the Drugs Controller General of India earlier this month, and is a critical aspect of ensuring that any vaccine procured through COVAX is fully quality assured.",
          "highlight_sentence_for_ai": false
        },
        {
          "generated_prob": 0.0002496192173566669,
          "perplexity": 34,
          "sentence": "According to the latest WHO update, a decision on this vaccine candidate is anticipated in the middle of February at the earliest.",
          "highlight_sentence_for_ai": false
        },
        {
          "generated_prob": 0.00017807881522458047,
          "perplexity": 34,
          "sentence": "COVAX also anticipates that, via an existing agreement with AstraZeneca, at least 50 million further doses of the AstraZeneca/Oxford vaccine will be available for delivery to COVAX participants in Q1 2021, pending regulatory approval by the WHO of the COVAX-specific manufacturing network for these doses.",
          "highlight_sentence_for_ai": false
        },
        {
          "generated_prob": 0.00018921321316156536,
          "perplexity": 41,
          "sentence": "A decision on this candidate is anticipated by WHO in the second half of February at the earliest.",
          "highlight_sentence_for_ai": false
        },
        {
          "generated_prob": 0.00027546577621251345,
          "perplexity": 94,
          "sentence": "\u201cThese purchase agreements open the door for these lifesaving vaccines to become available to people",
          "highlight_sentence_for_ai": false
        }
      ],
      "writing_stats": {},
      "result_message": "Our detector is highly confident that the text is written entirely by a human.",
      "result_sub_message": "",
      "document_classification": "HUMAN_ONLY",
      "version": "2024-01-09",
      "language": "en"
    }
  ],
  "editorDocumentId": null,
  "text": "Geneva/Oslo 22 January 2021 \u2013 COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income level, today announced the signing of an advance purchase agreement with Pfizer for up to 40 million doses of the Pfizer-BioNTech vaccine candidate, which has already received WHO Emergency Use Listing. Rollout will commence with the successful negotiation and execution of supply agreements. In further support of its mission to expedite early availability of vaccines to lower-income countries and help bring a rapid end to the acute stage of the COVID-19 pandemic, COVAX also confirmed today that it will exercise an option \u2013 via an existing agreement with Serum Institute of India (SII) \u2013 to receive its first 100 million doses of the AstraZeneca/Oxford University-developed vaccine manufactured by SII. Of these first 100 million doses, the majority are earmarked for delivery in the first quarter of the year, pending WHO Emergency Use Listing. The WHO review process, which is currently underway, follows approval for restricted use in emergency situations by the Drugs Controller General of India earlier this month, and is a critical aspect of ensuring that any vaccine procured through COVAX is fully quality assured. According to the latest WHO update, a decision on this vaccine candidate is anticipated in the middle of February at the earliest. COVAX also anticipates that, via an existing agreement with AstraZeneca, at least 50 million further doses of the AstraZeneca/Oxford vaccine will be available for delivery to COVAX participants in Q1 2021, pending regulatory approval by the WHO of the COVAX-specific manufacturing network for these doses. A decision on this candidate is anticipated by WHO in the second half of February at the earliest. \u201cThese purchase agreements open the door for these lifesaving vaccines to become available to people",
  "date": "28 January 2021"
}